Abstract 1481P
Background
ICIs have transformed the treatment of advanced NSCLC patients, no real-world data are available about the immune-related adverse events (irAEs). This retrospective study aimed to assess the safety and effectiveness of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer (NSCLC) and to analyze the association between singular irAEs and effectiveness.
Methods
This was a retrospective study of the clinical data of patients with NSCLC treated with PD-1/PD-L1 inhibitors as 1a or 2a lines from Marzo 2015 to Marzo 2022 at Hospital Universitario Regional de Málaga. We evaluated association of irAE with efficacy, response and overall survival. Kaplan-Meier and Cox proportional hazard analyses were performed.
Results
A total of 510 patients were included in this analysis. Any grade IrAEs were seen in 307 (60%) patients. Of these (Table), 135 (43,9%) patients had grade 1 toxicities, most commonly cutaneous (96), colitis (54), rheumatologic (46) and hepatitis (42). 112 (36,4%) patients had grade 2 toxicities pneumonitis (47), cutaneous (29), colitis (28). 53 (17,2%) patients had grade 3 toxicities: hepatitis (15), pneumonitis (13), cutaneous (10). 8 (2,6 %) patients had grade 4 toxicities hepatitis (5), pneumonitis (2), DRESS syndrome (1). For patients assessed for efficacy, objective response rate (ORR) to ICI was higher in patients with irAEs [46% vs 14%] p=0,001. In fact, the presence of any irAEs had a significantly improved median OS compared to those without irAEs (19,3 months vs 6,5 p = 0.0001) (Median OS in G1-2 20 months and G 3-4 16,2 months had significally higher OS vs non irAEs 6,1 months; p=0,0001). Singular toxicities that predict greater OS >30 months were (Hepatitis G4, endocrine G1 and cutaneous G2); point out toxicities with deleterious effects (colitis G3 and pneumonitis G4). Multivariable analysis demonstrated that the development of any irAEs was related to a significantly improved OS (HR 0.47, 95% 0.26-0.68, p = 0.0001).
Table: 1481P
Summary of singular toxicities and OS (overall survival) in months
IrAEsN 307 | Cutaneous 135 OS | Pneumo92 OS | Colitis89 OS | Hepatitis79 OS | Rheuma76 OS | Endocrine61 OS | Renal40 OS |
G1 135 | 96 28.2 | 29 18.3 | 54 21.4 | 42 18.7 | 46 28.8 | 40 37.8 | 19 21.4 |
G2 112 | 29 31.1 | 47 13.8 | 28 21.4 | 17 19 | 28 20.1 | 18 28.8 | 14 28.2 |
G3 53 | 10 13.4 | 13 15.3 | 7 7.2 | 15 20.6 | 2 3.8 | 3 - | 7 7.2 |
G4 8 | - | 3 1.9 | - | 5 40.6 | - | - | - |
Non N Ir 203 | 375 9.0 p=0.0001 | 418 11.4 p=0.54 | 421 11.2 p=0.018 | 431 11.6 p=0.146 | 434 11.1 p=0.001 | 449 11.1 p=0.001 | 470 12.6 p=0.05 |
Conclusions
This study confirms the feasibility and the safety of ICIs in a large, real-world cohort of patients with NSCLC. The development of irAEs in NSCLC patients treated with immunotherapy may predict better treatment efficacy and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21